RadioClash Inc. — SEC Form D Filing

RadioClash Inc. filed an SEC Form D on November 2, 2026, reporting $100K raised in Medical Devices.

Form D filing details

Filing
SEC Form D
Filing date
November 2, 2026
Amount reported
$100K
Round stage
Seed
Industry
Medical Devices
Website
https://www.radioclash.co/

What the company does

Securities: Equity. Exemption: Rule 506(b). Incorporated: TEXAS

Problem

Cancers of the liver, pancreas, and bones often present tumors that are inoperable or situated near critical structures where conventional treatments fall short.

Solution

RadioClash is developing an enhanced electroporation therapy platform that uses targeted electrical pulses to create irreversible nanopores in cancer cells, destroying tumors while preserving adjacent blood vessels, nerves, and healthy tissue.

Why now

Advances in image-guided interventional oncology and pulse-field/electroporation engineering allow non-thermal tumor ablation to replace highly morbid surgeries with precise, outpatient-compatible procedures.

Verdict

Investors treated this sub-$100k check as a speculative option on non-thermal pulsed-field ablation, betting that proprietary waveform tuning could crack unresectable margins where thermal methods fail. This cleared because the clinical utility of irreversible electroporation near critical structures was already validated by NanoKnife, not because RadioClash proved differentiated clinical safety or procedural efficiency. Upside remains severely capped by the brutal capital requirements of interventional device commercialization against well-capitalized incumbents who already own the catheter lab real estate.

Source: SEC EDGAR Form D filing